– Enrolling patients in proof-of-concept exploratory trial conducted in collaboration with the University Hospital Basel in Switzerland and Maastricht University in the Netherlands – -Trial led by Dr. Matthias Liechti and Dr. Kim Kuypers, pioneers and leading global experts in the psychedelic landscape – NEW YORK, Dec. 17, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE…


Previous articlePsychedelics and Substance Use Disorder: 4000 BCE to Present Day
Next articlePTSF89 – A Macro Dive Into Microdosing